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segments witl~ al~normal wall motion, 51 segments wore aklnetlc or dyekt- 
nolle, 
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Tott~l 30 15 51 Total 30 15 61 Total `34 15 40 
'F/U: follow up ocho(~lr,.llogr=tphy, ~.: Vlnl)lo, ; r, on,vlnblo 
OSE and ~OqTi h~d the @time sonsBivity of 83% and tl~o similar spoctflclty, 
87% vs 03%, positive prodlct~billty, 04% v~ 97% and nogallvo predlcatUillty 
66% ve '/0% In ptodicllng contreo!tlo recovery, However, MCE Itad the higher 
genslllvtty: 100% and negative prodtc~lablllly', t00% (p ,  0,01 ), but the lower 
spocitlclly', 60% end po~ittvo prodteleblllty: fig% (p • 0,05) comp~nng with 
DSE and ~0~ TI, 
In conglu~lon, contraotllo reserve and cell membrane Integrity alter re. 
ct~n~llzatlon ol IRA Imply a I_~to contractile rocevon/but mlcrov,~scular in- 
tegrity tmmedl(~tely alter roc~nallzalion does not nocosearily imply n late 
contractile recovon/, 
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~ Ident i f icat ion of  Pat lanta With Improvement  o f  LVEF 
and Heart Failure 8ymptome by Combined Low.High 
DoN Dobutomlno E©hocardlogrnphy 
J.J, B~x, J.H, Cornel ~ . D, Potdern~rln~l ,A, Elheady;', E, Ooorsma;', 
P,M, Florotti :f, Leiden, The Netttorl~nds: 'Atknmar, Tltu N~thod~md~: 
"~ Rotto~m, The Nothorl~lnd~ ; " Udino, Italy 
Oobut~mine stress.echo (DSE, combined low, ~nd high-dose) cnn be used to 
pre~llct improvement ot LVEF niter rovosculatlz~tlon, tt is unknown whether 
the technique can also Identlly patients who may Improve in heart faduro 
(HF) symptoms, We evaluated the u~e oi DSE to identify patients with 
improvement of LVEF and HF symptoms alter rovaseulnnzatlen, Patients 
(n ,~ 62) with chronic coronary adory dtseaso and LVEF .: 35% underwent 
DSE (16-segment model) before rovascularlzatlon, Criteria for viability were 
a blph0,sl¢ response, sustained improvement or worsening of wall motion 
during DSE, LVEF was assessed by radionucllde ventrculography before 
and 3 months alter revnscularl;tatlon Improvement ot LVEF was delined by 
an increase of LVEF by ::5%, HF functional class was assessed bolero and 3 
months alter revascularlzatlon, Twenty-one patients lmprevod ~:5% In LVEF 
alter the rovasculanzation (26 t 7% versus 34 ~ 7%) while 41 remained 
unchanged (29 * 5% versus 28 :t 5%), The patients with an improvement 
of LVEF ~:5% e~hibited significantly more viable segments on DSE (5.5 
2.2 versus 1,7 ~ 1.4, P - 0,01), Twenty-two patients (group l) had :4  viable 
segments on OSE, wl~ile 40 had • 4 viable segments (group II), In group I 
the LVEF increased from 27 t 6% to 33 I 7% (P.  0,05) and the HF class 
decreased (2.5 t 09  vs 1.6 t 06, P • 005). In group II LVEF (29 :t 5°0 vs 
28 i 6%, NS) nor HF functional class (2.5 ~ 0,5 vs 2,6 t 0.0, NS) improved. 
In conclusion, substantial viability on DSE helps to identify patients who may 
improve In LVEF ~nd HF symptoms after rovascularization. 
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~ Nlsoldiplne Echocardlography: A New Method for  
Assessing Myocardial Viability Alter Acute 
Myocardial Infarction Treated With Thrombolysls 
S, Rosanio, I, Shoiban, S, Tonni, M, Toechi, A. Anzuini, G. Rosano, 
P Pagnotia, M Mentodano. S, Chierehia. H.$.R.. M#an: University of 
Verona. Verona. Italy: U,'£M,B., Galveston. TX, USA 
Background: Previous clinical studies h~ve shown that the i,v, admmistratton 
ot nisoldipine (Nis), a highly specific dihydropyridtne calcium antagonist, can 
recruit an inotropic reserve in stunned myocardium Mechanisms of improved 
contractility may include increase in coronary blood flow, LV alterload reduc- 
tion and improved myocyte calcium handling. However. the potential value 
et Nis echocardiography (Nis-E) in detecting myocardial viability after acute 
myocardial infarction (AMI) has never been tested. 
Methods: In this study. 30 consecutive pts (age 55 :t 8 yrs; 19 m) under- 
went Nis-E end rest - 4 h redistribution Thallium-201 SPECT (TI) at 8 ~. 2 
days after uncomplicatect hrembolyzed AMI (17 anterior site). A 16-segment 
4-grade score model was used tor ~nalysis of both Nis-E and TI. Nis was 
given Lv, in a dose of 3 mcg/kg over 5 min and 2D echocardiograms were 
continuously obtained and intermittentiy recorded during and up to 20 rain 
alter drug administration. Viability was defined as wall motion score improve- 
ment during Nis-E -1 grade or as Thallium uptake :60% at rest or upon 
redistribution. 
Resu;ts: Nis-E was completed in all pts without signilicant side effects or 
development of echo Or ECG signs of ischem~a. Overall 89 basally asyn- 
ergic segments were scored. Nis-E and TI had concordant results in 26/31 
(84%) TI-viablo segments and 55/58 (95°/,,) TI-nonviable segments, When 
comparod with quantitative TI uptako analysis, the same NIs.E.viablo or 
• nonvleblo segments sltowed an avomgo % TI activity o! 75 :t 7% and 39 
10%, mspoctlvaly (p ,~ 0,01), At follow-up (4,5 :t 1,5 months) rest echo, 23 
o! 26 Nls.E.vlable and 9 ol 55 NIs.E-nonviablo segments had a functional 
mceven/(88% vs 16%; p • 0,01), 
Conclusions: NIs.E in the early post.AMI period is a safe, oltectivo a~l 
relatively inexpensive method let assossing myocardial viability: 
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~ l 'he  Impact of 8ubendocardlal 8carting on 
Prodi©tlon of Improvement of Rsglonal Wall Motion 
Alter Ravaecularl,atlen by Dobutamlne 
Echo©ardlography 
J,J, BOIX, JH, Cornel I , A, Elhondy ~, O, Poldorm~ns ~, P,M, FioraltP, 
J,R,T,C, RoolandP', L~idon, Tho NoflvorhmoL~: t AIkm~l(Ir, The N~fhe~l~nd~; 
~'Roffo~d~m, The Nethed~nds; 'rUdlno, It~ly 
The amount el 5car i5 [ol~tQd to the seventy el the testing w~,ll met=on ~b, 
norm~lw: mild dy~synorgy is !roqgently ebson/od in 5~_I-rl'~ndoc~]t~ial ,~ r~, 
while severe dysSynetgy occur~ in tr~nsmu[~l sc~r~. We ccJmp~t~ rh~ ~,e- 
carney el low-dose debut~mino echo to predict improvement el tunction ,~lter 
rov~l_seulari;tation (REV) in ~ovorely versus mildly dys,~yner~i¢ my~:;~lium 
Patients (n - 91) wllh chronic, i~chemic LV dysfunction who were ~hod- 
uled ler REV were mcludod~ All underwent Iow.Uoso dobutsmino (5 ~r 10 
~glrg/mint eehoc~rdtogr~]phy before the REV, Contractile me.errs dune 9 !ow- 
do~o dobutamino infusion was considered indicative tot fanctlona~ r~ovefy. 
Improvement el function after the REV was assessed by resting e~hocar. 
diogrophy bolero and 3 months a~or REV. 622 segments were dyswnorgic 
(263 mild dyssynorgie, 359 severe dyssynerg¢). Contractile reserve was 
pro~enf in 191 (73%) el the mildly dyssynorgie segments and in 138 (38%) 
o! tire severely dyssynergic 3egments, Recoven/of function occurr~J dn 84 
(32%) mildly dyssynergio segments and in 89 (25%) severely dyswnergic 
segments. The sensitivities ol dobutamine echo were 96% and 89% iNS) in 
mildly and severely dyssynorg~c segments, while the specilicities were 39% 
and 7B% respectively (P - 0,05). The sl~il ieity dn mildly hypokinetic see, 
meals was also lower in patients with non-Q wave infamtion versus patients 
with a Q wave (29% versus 40%). Thus, specificity was significantly lower 
in mildly dyssynergic segments, suggesting overestimation of recover/and 
appears to be related to the presence of subendecardial scar. 
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~823-1 I Inc reased  Circulat ing Soluble Fas In Pat ients With 
Di lated Cardlomyopathy 
Y. Shigematsu, H. Kawakami, 1". Ohtsuka, H. Okayama, Y. Hayashi, Y. Hare. 
K. Kodama, M Hamada, P. Qu, K. HLwada. Ehime UniverSity, Ehime. Japan 
Background: Apoptosis in myocyte has been demonstrated. However, wheth- 
er this form of myocyte death occurs in the tailing human head is not com- 
pletely understood. In this study, we assessed plasma soluble Fas (sFas) as 
an index of Fas-Fas Ligand system activation and the presence of apoptosis 
in dilated cardiomyopathy. 
Mehod$: sFas was measured by enzyme-linked immunosorbent assay. 
Plasma sFas levels were measured in 33 patients with dilated cardiomvepa- 
thy (DCM) and 1'2 age-matched normal controls iNCl. 
Results: Plasma sFas levels in patients with DCM were significantly higher 
than those in NC (2.42 : 1.02 vs 1,66 ± 0.20 ng/ml, p = 0.015). Patients with 
DCM were divided into two groups according to plasma sFas. Group I (n = 
15): plasma sFas levels were less than the mean value + 2SD in NC. Group 
II (n = 18): plasma sFas levels were higher than the mean value + 2S r') in 
NC. 
sFas fngJml) LVDd (mm) LVDs (mm) FS t°o) 
Group I 1,68 ± 0.18 694 t 7 5 57.4 ~ 8.4 17.6 ,.., 4,7 
Group II ~.00 ~ 058" 70.0 .* 7.1 59 4 L 9.2 148 t 73 
These values are mean ~_ SD, LVDd = left yen!titular arid-alias!cite Uimension. LVDs = left 
ventrtcutar end-systolic dimension. FS = tractqonal shortening, "p . 0.00Of vs el'cup L 
There were 5 deaths for worsening heart failure in group II, but there was 
no death in group I during follow-up period (34 ± 11 months). In addition, 
there was a good positive relation between plasma sFa~ levels and New York 
Heart Association (NYHA) functional class (r = 0.76, p < 0.0001 ) in patients 
with DCM. 
JA('(, I;ehnt:lp, I'~):~ AI|STRAC[S ()r,d 8)lA 
Conctusmn: Plasma sFos I~vels wen elovat~l in pattents w~th DCM 
One important mechanism of myoo~e (loath in DCM may be Fas.mod~ated 
opoptosis Plasm,~l 6Fas in p~ttents with DCM provl~ progr ~eti~ mformabon 
in@0pendenl of carUia¢ function. 
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~ Anglot~n=ln Converting Enzyme Inhlbitom Have a 
Nittla Oxide Modulated Negative Inotmpl¢ Effilct in 
Patients With left Ventd©uklr I~/Munetlon 
IS, Wttt~t~m, D,A, K~s~, WL M~uoj~n, PH P~k, B Fet~, JM. Hare 
Jom~ H~km~ Un~v~ty ~t~ ot ~,~n~ LG~lt~mom, Me, USA 
Nifr~ ox~ (NO) has ~o shov~ to tahit i  th~ ll,adr(~PaprOiC nolropIc re- 
sponge in humans with lelt v~'~tnCul~r dyslgP,¢llOn. Ang~olgnstn (;onvo~llng 
orb/me (ACE) inhtt~t(~s *~roa~ bradykl~n, an a0or~sl of NO fy~th,~_, by 
mhi~tirlej kir~n,~5~ tl. We hypot t~ed their ACE tnhibitors woel(~ pr~e a 
NO o~ldu!ate~ n~f lve  inoirop~c ett~:;l i ~ n t  Of ~og~ten,~_in r~¢elP 
tor.t (AT--!), Ei~l!t I~tv~nts will1 e~l(tl~l C-dr~komyop~thy were with~raJwn hem 
AC_E inht~!ot.5 cj~t~ v~¢k I~fo~ ~tu4ly ~,'~ ~tt~1~l on tha AT.1 r0¢e_pter ~n: 
ta~iSt  Io~fti~n (50 m~l (~0). In t rover t  (Iob~Jt~lm4ne (0) at 5-~-- 10 ~,g/kg/mm 
w~S ~mmister~l to ach~wo ~ 49 *- 8% increase_ in peak *dP/~ (p -: 0.001) 
En~laWdat was in tu~ into the lelt main coronary ade~ (0.~ moJmin for 
15 mmutes; O * E) and Contin~l d~nng the infu~oo of the NO synthaso 
inht~for L.N~-monemelhyl.arojnin~ (L.NMMA, 5 mr/rain for 10 minutes: D + 
E + L) Leh ventncu!ar Wstol~: (LVSP) and end ~astolic (LVIEDP) pressures, 
6ystotic blQo(l pressure, and peak *dPldl were measured dunng these m- 
lusionS. Chanoj~s in *dPzdt relative 1o baseline are shown (p - 0.0_5 vs O 
and D + E + L)~ Thus. enalapnlat resulled in a redection in the dobutamine- 
stimulated -H:lP~dt resix~se, and this effecl was reversed by L-NMMA. There 
was no change in LVSP. LVEDP. and systolic blood pressure, demonslral]ng 
that the effect of enaJap~lal on myocardial contractility was independent of 
loading condihons 
[ 
" °ik d 
0 
D DeE D-E*L 
These data suggest that ACE inhibtters may have a NO mediated, AT-1 
receptor independent influence on myocardial contractility. This i~ntlon may 
contribute to the therapeutic effects of ACE inhibitars in the management of 
I~ad fadure by vidue of a pest-receptor #-blockmg effect. 
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~3-~ Re¢omhinant Human B-type Paptide Natriuretic 
Improves Symptoms and Hemodynamics in Patients 
With Acutely Decompensated CHF 
T.H. LeJemteP, RC Bourge. AD. Johnson. D.P Hodon. WS. Cotuccl 2 
Albert Einstem College o! Medicme. USA : :Boston Univets~/ School el 
Medtcine. NY. USA 
Recombinant human B-type nalnuretic pepbde (rhBNP). produced usmg a 
fusion protein in Esche[ichia coil, is identical to endegeno,:-~ hBNP bul has 
not been previously studied in humans. In a randomized, placebo-controlled. 
muiticenter, double-blind study, effects of a continuous infusion of 2 doses 
of thBNP on symptoms and hemodynamics were assessed in 127 patients 
with acutely decompensated congestive heart failure (CHF). At basetine, 
80% of subjects had dyspnea at rest or with minimal exertion. Their median 
pulmonaw capillary wedge pressure (PCWP) was 28 mm Hg and median 
cardiac index (CI) was 1.9 LJmin/m 2. Endpdints included symptoms (based 
on physician assessment of a 5 point symptom scale). PCWP. CI. head rate 
(HR). and blood pressure (BP). 
Results: After 6 hours ef infusion, dose-rel~;=d !,~prevements in symp- 
toms, PCWP, and CI occurred with no change in HR. Mild decreases in BP 
(median decrease of 7% vs. baseline) were well tolerated. Symptom (Sx. °o 
of subjects improved) and hemodynamics (median Oo change from baseline) 
results are presented below: 
Endpoint Placebo n = 42 0.015 H/kg/min  = 43 0.03 #/kglmin = 43 
Global Sx (°=, improved) 5 48" 69"" 
Dyspnea (% improved) 12 55"" 50"" 
PCWP (% change) +7.3 20.0- - 31.6"" 
CI (% change) 10.9 +5.4" +20 3"' 
'p- 0.05and"p- 0.005 versus placebo. 
Conclusions: A continuous infusion of rhBNP 1) safely and rapidly im- 
ploves ~lobal ¢11n¢,~1 st~lus, 0ySl;,noa, and I(dt ~tncu lar  p~orm~nce m 
patients with acutely (~o¢ompol'..$~ted CHF, wlti"~o~t ncreasing lu~fl eats 
ai~l ;~) causes dose--~1;_i~n(~tent improvcrncnts m wm~toms an~ r~=mo~ 
namlcs "thus r¢.combnant hBNP is an effect=re agent to1 ft~ri~y el ~¢ut,~ly 
~compens~tcd CHF 
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.Zndethelln El'= Rq~ptor= =~ Functionally 
important in Medlar|no VIl¢oconotdctlon In the 
8ylltemi¢ C|rcuiatlon In Petkmt| With Left 
Vontfleuiar DyMunetlan 
P J  Cowbum, J,J, Morton, J.O McA~hur, M,R, MacL~em, H J  Oar~p, 
J JV  M.cMuffay, JG,F, Clel0n~L Chl~.~l R~,,lrch I~f~v~ in I,,le~rt Fadgre, 
Uruvemty ot ~ and W~lem lnr~rma~ Gla~ow, ~,and, UK 
Th~ fLInctlof~l fitgnlt~L:e of E--r,~ ~n¢l ~o  receptors in chronic PaC~rt failure (~ 
not ¢l(~i~r. [nck~thehn (lET).3 ~ 6©loclivo ~TB r~¢~plof agonisl, is a le_ss I~tent 
v~.~0consthclor at eternal forearm resisEmce veSSels than ST.1, non_ .[v~=!L~.= 
,vo ST^ and Era rl~Ceptor i~gOfll~t. We intuse¢l ~T.1 (5 aP~ 15 pmoUmm) 
into 8 pQtients with left ventricul~r dystgnct~n (LVD) and ET.3 (5 and 15 
prnoI/m~n) into a further 8 pah,Jnts with LVD with 5imtl~r be~tine h(m~ly- 
nam.,C iodces. Hemndynamtcs were measgreO by thermo~ut~on call. let 
and arterial ine. Results are eJ~pressed as mean * st~n~_= r~t ~vi~,tlon ET-1 
ancl Er.3 values are ~ven tar the 15 pmol/~n dose. 
Basez~ne ET, 1 Baseline lET,3 
HR 73 : 18 73 * r6 67 .* 14 68 r 16 
MAP 100 : 8 105 • 8' g9 • 17 105 = 17" 
RAP 6 ; I  5 r2  6z;2 6z2 
MPAP 21 : 6 2z -, '~ 19 z 4 ~1 ± 5 
PC1NP 13 ~ C 1~ ~ 7 12 I 4 13 : 5 
C| 244 : 0 58 2 22 : O 5F" 2 ~ ~ 0 79 242 t 067" 
SVR 1727 ; 403 2054 : 465" 1639 t 593 t916 t 692" 
PVR 152 ~ 44 149 : 41 122 t 37 132 z 39 
"p 065 ""p 001 
Exogenous Er-1 and ET-3 caused systemic but not pulmonary vasocon. 
stnction in patients with LVD Tr~ hem0dynamic hanges were of a similar 
magnitude at the same motae concentration. This suggests that ETa resep* 
tars are functionally irnporbmt ,n mediating vasnconstnction in the systermc 
circulation in patients with LVD 
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~Lef t  Ventricular Remodelling 6 Months After 
Infarction is Predicted by Myocardial 
/3-Adtenoceptor Oensity at 1 Month 
N. Spyreu, SD. Rnser,. R Foalo, WD Dawes, PG Camicl. MRC Cyclotron 
Uni Hammersnuth Hompi~l a3ci Chmcal Cardiology St. Mary's Hospital, 
ICSM. London. UK 
Background: Following ac,,te myocardial mfarction (AMI) there is evidence 
of sustained sympatPettc ovoracbv,ty which has been shown to contnbute to 
le;t venthcular (LV) remodelling =n ancma! models. Increased tissue levels of 
nerepmephrine lead to a reducbon of 6-admnoceptor (/fAR) density which 
can be measured noninvas=vely ~th positron emission tomography (PET). 
We aimed to assess: 1- if there is a reduction of myocardial pAR density 1 
month after AMI and 2- if this correlates with changes in LV volumes at 6 
months. 
Methcds: We studied 42 patients aged 53 =, 12 years with AMI and no 
previous angina, diabetes, hypertensz0n Or renal disease. All had single ves- 
sel disease. LV end-systohc (ESV) and end-diastolic (EDV) volumes were 
s.~Ressed 1 week and 6 months after AMt by echocardiography. Changes (A) 
in ESV and EDV were calculated by dividing the 6 month by the 1 week re- 
suit. Myocardial pAR density and coronary vaSOdilalor eserve (CVR, dipyfi. 
darnels) were r,~easured 1 month after AMI with PEr using "CGP-12177 
arid H2150 respectively. PET data in patients were compareO with those m a 
group of 18 age-matched controls. 
Results: ESV was 61 ~ 20 ml at 1 week and 64 : 28 ml at 6 months (p 
= ns) and FDV was 111 = 31 and 121 ~ 40 ml respectively (p = ns). The 
patients had lower pAR density (5.95 c 0.99 vs 8.35 ~: 2.00 pmol/g, p = 
0.0001) and CVR (1.81 ± 0.75 vs 3.22 • 1.19. p = 0.0001) than controls. In 
patients there was an inverse correlation between pAR and ~EDV (r = 0 42. 
p = 9.006) and between CVR and AESV (r = 0.33, p = 0.04) and AEDV (r = 
0.38. p = 0.05). 
Conclusion: 1. There is a significant downregulation of myocardial/~AR 1 
month pest AMI which predicts an increased EDV at 6 months: 2. There is 
an inverse correlation between CVR and deterioration in ESV and EDV. 
